Clinical Trial Update: Ribavirin Dose Optimization for the Treatment of Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reporting ribavirin dose optimization for chronic hepatitis C; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED